Vividion Therapeutics, a preclinical oncology biotech developing small molecule therapies, withdrew its plans for an initial public offering on Friday. It originally filed in June 2021 with a proposed deal size of $100 million, and earlier this month announced that it would be acquired by Bayer AG for as much as $2 billion.
The San Diego, CA-based company was founded in 2013 and booked $43 million in collaboration revenue for the 12 months ended March 31, 2021. It had planned to list on the Nasdaq under the symbol VVID. J.P. Morgan, BofA Securities, and Jefferies were set to be the joint bookrunners on the deal.
